We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the last reported quarter, the company’s earnings missed the Zacks Consensus Estimate. It delivered an average earnings surprise of 0.6% in the past four quarters.
The Zacks Consensus Estimate for revenues is pegged at $940.6 million. The consensus mark for earnings is pinned at 48 cents per share.
Factors to Note
DENTSPLY SIRONA’s Orthodontic and Implant Solutions segment witnessed organic revenue growth in the last reported quarter on the back of strong demand for SureSmile, which continues to benefit from market share gains and new product offerings. Per management, the company is likely to expand further in certain international markets, including Japan and Brazil, which is likely to lead to SureSmile's continued momentum. The company’s expectation of SureSmile growing more than 20% in 2024 is likely to have been reflected in the quarterly performance.
XRAY’s Aligners saw growth in sales in the last reported quarter. Improved customer conversion rates and lower customer acquisition costs benefited aligner brand Byte. The trend is likely to have continued in the quarter to be reported. In September, XRAY introduced a new, versatile and innovative intraoral scanner, Primescan 2, further aiding the top-line growth.
In the first half of 2024, XRAY’s Connected Technology Solutions segment’s top-line performance declined significantly and the company expects further decline in the upcoming quarters. However, management expects to witness some improvements in the latter half of the year compared with the first. The CAD/CAM segment is likely to have witnessed growth in the to-be-reported quarter on the back of increasing demand.
DENTSPLY SIRONA’s Wellspect Healthcare business reported strong growth in the last reported quarter. The company expects this segment to have improved further in the quarter to be reported.
For the third quarter, XRAY expects organic sales to have declined from the prior-year level, with slightly lower reported sales due to a negative impact of foreign currency movement. However, on a sequential basis, the reported sales are expected to have increased, based on normal seasonality. XRAY anticipates adjusted EPS to have been down slightly year over year, primarily due to a higher tax rate, partially offset by a slight improvement in adjusted EBITDA margin.
What the Zacks Model Unveils
Our proven model does not conclusively predict earnings beat for XRAY this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is +0.84%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: DENTSPLY SIRONA currently carries a Zacks Rank #4 (Sell).
Stocks to Consider
Here are a few medical stocks worth considering, as these have the right combination of elements to come up with an earnings beat this reporting cycle.
The company is likely to release third-quarter 2024 results on Nov. 5. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.63%. The Zacks Consensus Estimate for EPS implies an improvement of 33.3% from the year-ago figure.
ACADIA Pharmaceuticals (ACAD - Free Report) has an Earnings ESP of +17.23% and a Zacks Rank #3 at present. The company is expected to release third-quarter 2024 results on Nov. 6.
ACAD’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 42.37%. The Zacks Consensus Estimate for EPS implies a surge of 127.5% from the year-ago recorded figure.
Becton, Dickinson and Company (BDX - Free Report) has an Earnings ESP of +0.32% and a Zacks Rank #2 at present. The company is expected to release fourth-quarter fiscal 2024 results on Nov. 7.
BDX’s earnings beat estimates in three of the trailing four quarters and met once, the average surprise being 6.24%. The EPS is expected to improve 10.2% from the year-earlier reported loss.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Should You Buy, Sell or Hold DENTSPLY SIRONA Before Q3 Earnings?
DENTSPLY SIRONA Inc. (XRAY - Free Report) is scheduled to release third-quarter 2024 results on Nov. 7, before the opening bell.
In the last reported quarter, the company’s earnings missed the Zacks Consensus Estimate. It delivered an average earnings surprise of 0.6% in the past four quarters.
Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.
Q3 Estimates
The Zacks Consensus Estimate for revenues is pegged at $940.6 million. The consensus mark for earnings is pinned at 48 cents per share.
Factors to Note
DENTSPLY SIRONA’s Orthodontic and Implant Solutions segment witnessed organic revenue growth in the last reported quarter on the back of strong demand for SureSmile, which continues to benefit from market share gains and new product offerings. Per management, the company is likely to expand further in certain international markets, including Japan and Brazil, which is likely to lead to SureSmile's continued momentum. The company’s expectation of SureSmile growing more than 20% in 2024 is likely to have been reflected in the quarterly performance.
XRAY’s Aligners saw growth in sales in the last reported quarter. Improved customer conversion rates and lower customer acquisition costs benefited aligner brand Byte. The trend is likely to have continued in the quarter to be reported. In September, XRAY introduced a new, versatile and innovative intraoral scanner, Primescan 2, further aiding the top-line growth.
In the first half of 2024, XRAY’s Connected Technology Solutions segment’s top-line performance declined significantly and the company expects further decline in the upcoming quarters. However, management expects to witness some improvements in the latter half of the year compared with the first. The CAD/CAM segment is likely to have witnessed growth in the to-be-reported quarter on the back of increasing demand.
DENTSPLY SIRONA’s Wellspect Healthcare business reported strong growth in the last reported quarter. The company expects this segment to have improved further in the quarter to be reported.
DENTSPLY SIRONA Inc. Price and EPS Surprise
DENTSPLY SIRONA Inc. price-eps-surprise | DENTSPLY SIRONA Inc. Quote
For the third quarter, XRAY expects organic sales to have declined from the prior-year level, with slightly lower reported sales due to a negative impact of foreign currency movement. However, on a sequential basis, the reported sales are expected to have increased, based on normal seasonality. XRAY anticipates adjusted EPS to have been down slightly year over year, primarily due to a higher tax rate, partially offset by a slight improvement in adjusted EBITDA margin.
What the Zacks Model Unveils
Our proven model does not conclusively predict earnings beat for XRAY this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is +0.84%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: DENTSPLY SIRONA currently carries a Zacks Rank #4 (Sell).
Stocks to Consider
Here are a few medical stocks worth considering, as these have the right combination of elements to come up with an earnings beat this reporting cycle.
Masimo (MASI - Free Report) has an Earnings ESP of +0.40% and a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The company is likely to release third-quarter 2024 results on Nov. 5. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.63%. The Zacks Consensus Estimate for EPS implies an improvement of 33.3% from the year-ago figure.
ACADIA Pharmaceuticals (ACAD - Free Report) has an Earnings ESP of +17.23% and a Zacks Rank #3 at present. The company is expected to release third-quarter 2024 results on Nov. 6.
ACAD’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 42.37%. The Zacks Consensus Estimate for EPS implies a surge of 127.5% from the year-ago recorded figure.
Becton, Dickinson and Company (BDX - Free Report) has an Earnings ESP of +0.32% and a Zacks Rank #2 at present. The company is expected to release fourth-quarter fiscal 2024 results on Nov. 7.
BDX’s earnings beat estimates in three of the trailing four quarters and met once, the average surprise being 6.24%. The EPS is expected to improve 10.2% from the year-earlier reported loss.